My watch list
my.bionity.com  
Login  

Dalbavancin



Dalbavancin
Identifiers
CAS number
PubChem 16134410
Properties
Molecular formula C88H100Cl2N10O28
Molar mass 1816.6918
Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

Dalbavancin, a novel second-generation lipoglycopeptide agent, belongs to the same class as vancomycin, the most widely-used and one of the few treatments available to patients infected with MRSA.[1]

It possesses in vitro activity against a variety of gram-positive pathogens[2][3] including MRSA and MRSE. [4]It is a once-weekly, two-dose antibiotic that Pfizer acquired when it bought Vicuron Pharmaceuticals in 2005.[5]

References and notes

  1. ^ Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration
  2. ^ Chen AY, Zervos MJ, Vazquez JA (2007). "Dalbavancin: a novel antimicrobial". Int. J. Clin. Pract. 61 (5): 853–63. doi:10.1111/j.1742-1241.2007.01318.x. PMID 17362476.
  3. ^ Das B, Sarkar C, Biswas R, Pandey S (2008). "Review: dalbavancin-a novel lipoglycopeptide antimicrobial for gram positive pathogens". Pak J Pharm Sci 21 (1): 78–88. PMID 18166524.
  4. ^ Dalbavancin: A Novel Lipoglycopeptide Antibacterial
  5. ^ UPDATE 1-Pfizer says US FDA wants more data on antibiotic
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dalbavancin". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE